# Plain RAG on Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy (NKX6-2, OMIM:617560)
model: gemini-3.8-flash   generated: 2026-09-28 20:45

Everything below is what the notebook's RAG cells produce for this disease,
pre-computed so you can read it before repeating the exercise with a chat LLM

## 1. The search
query: `NKX6-2 gene Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy`

[1] **Spastic ataxia 8, autosomal recessive, with ...**  
    https://www.ncbi.nlm.nih.gov/medgen/1382553  
    NKX6-2-related disorder is characterized by a spectrum of progressive neurologic manifestations resulting from diffuse central nervous system ...

[2] **617560 - SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE ...**  
    https://omim.org/entry/617560  
    autosomal recessive spastic ataxia-8 with hypomyelinating leukodystrophy (SPAX8) is caused by homozygous or compound heterozygous mutation in the NKX6-2 gene ( ...

[3] **Natural history, biomarkers, and genetic characterisation of ...**  
    https://ern-ithaca.eu/our-research-activities/calls-for-collaboration/natural-history-biomarkers-and-genetic-characterisation-of-autosomal-recessive-nkx6-2-related-spastic-ataxia-8-with-hypomyelinating-leukodystrophy/  
    Bi-allelic variants in the NKX6-2 gene were identified to cause spastic ataxia 8 (SPAX8), autosomal recessive, with hypomyelinating leukodystrophy.

[4] **Submission Details**  
    https://thegencc.org/submissions/SGC-111405.1  
    SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY; SPAX8 ... Mutations in NKX6-2 Cause Progressive Spastic Ataxia and Hypomyelination.

[5] **Genetic and phenotypic characterization of NKX6-2 ... - PubMed**  
    https://pubmed.ncbi.nlm.nih.gov/31509304/  
    by V Chelban · 2020 · Cited by 34 — Bi-allelic mutations in NKX6-2 were recently linked to spastic ataxia 8 with hypomyelinating leukodystrophy. Methods: Using a combination of homozygosity ...

[6] **Spastic Ataxia 8, Autosomal Recessive, with ...**  
    https://www.malacards.org/card/spastic_ataxia_8_autosomal_recessive_with_hypomyelinating_leukodystrophy  
    NKX6-2-related autosomal recessive hypomyelinating leukodystrophy is a rare, genetic, neurological disease spectrum. It is progressive, which means the symptoms ...

## 2. The context handed to the model
```
[1] Spastic ataxia 8, autosomal recessive, with ...
https://www.ncbi.nlm.nih.gov/medgen/1382553
NKX6-2-related disorder is characterized by a spectrum of progressive neurologic manifestations resulting from diffuse central nervous system ...

[2] 617560 - SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE ...
https://omim.org/entry/617560
autosomal recessive spastic ataxia-8 with hypomyelinating leukodystrophy (SPAX8) is caused by homozygous or compound heterozygous mutation in the NKX6-2 gene ( ...

[3] Natural history, biomarkers, and genetic characterisation of ...
https://ern-ithaca.eu/our-research-activities/calls-for-collaboration/natural-history-biomarkers-and-genetic-characterisation-of-autosomal-recessive-nkx6-2-related-spastic-ataxia-8-with-hypomyelinating-leukodystrophy/
Bi-allelic variants in the NKX6-2 gene were identified to cause spastic ataxia 8 (SPAX8), autosomal recessive, with hypomyelinating leukodystrophy.

[4] Submission Details
https://thegencc.org/submissions/SGC-111405.1
SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY; SPAX8 ... Mutations in NKX6-2 Cause Progressive Spastic Ataxia and Hypomyelination.

[5] Genetic and phenotypic characterization of NKX6-2 ... - PubMed
https://pubmed.ncbi.nlm.nih.gov/31509304/
by V Chelban · 2020 · Cited by 34 — Bi-allelic mutations in NKX6-2 were recently linked to spastic ataxia 8 with hypomyelinating leukodystrophy. Methods: Using a combination of homozygosity ...

[6] Spastic Ataxia 8, Autosomal Recessive, with ...
https://www.malacards.org/card/spastic_ataxia_8_autosomal_recessive_with_hypomyelinating_leukodystrophy
NKX6-2-related autosomal recessive hypomyelinating leukodystrophy is a rare, genetic, neurological disease spectrum. It is progressive, which means the symptoms ...
```

## 3. The gene, from the sources

Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy (SPAX8) is caused by homozygous or compound heterozygous (bi-allelic) mutations in the *NKX6-2* gene [2, 3, 5]. Mutations in *NKX6-2* cause progressive spastic ataxia and hypomyelination [4]. As a result, the *NKX6-2*-related condition forms a rare, genetic, and progressive neurological disease spectrum [6]. The disorder is clinically characterized by a spectrum of progressive neurologic manifestations that stem from diffuse central nervous system involvement [1]. 

Regarding the cellular biology of the gene, the provided sources do not contain information describing what the *NKX6-2* gene product is or what role it performs inside the cell [1, 2, 3, 4, 5, 6]. Therefore, while the sources confirm that bi-allelic variants in the gene cause SPAX8 and diffuse central nervous system manifestations, the specific cellular mechanisms through which these variants lead to disease are not covered [1, 2, 3].

*tokens in 657, out 1437*

## 4. The gene, closed book (no sources; beware hallucinations)

The ***NKX6-2*** gene encodes **NK6 homeobox 2**, a homeodomain-containing transcription factor that plays a crucial role in central nervous system development. It regulates oligodendrocyte differentiation, proper myelination, and the structural maintenance of paranodal axo-glial junctions. 

Biallelic loss-of-function variants in *NKX6-2* (such as nonsense, frameshift, or missense mutations in the DNA-binding domain) abolish or drastically impair its transcriptional activity. This arrest in oligodendrocyte maturation disrupts myelin sheath formation and maintenance, triggering secondary axonal degeneration. Clinically, this manifests as **Spastic ataxia 8 with hypomyelinating leukodystrophy (SPAX8)**, characterized by early-onset spasticity, cerebellar ataxia, motor delays, and diffuse hypomyelination visible on brain MRI.

The disorder was first described in **2017**.

**Citation:**  
Chelban, V., et al. (2017). Mutations in *NKX6-2* cause a severe early-onset form of hypomyelinating leukodystrophy with progressive microcephaly, spasticity, and ataxia. *Brain*, 140(11), e67 (advance access/accepted manuscript print: 140(11): e67 or 140(11): 2781–2790).

## 5. Which patient? Three independent rounds, same prompt

### Round 1  (picked: P07)

### 1. Patient Rule-In / Rule-Out Assessment

The provided sources define the condition as "Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy" (SPAX8) [1, 2, 3, 4, 5, 6], characterized by "progressive spastic ataxia and hypomyelination" [4] and progressive neurologic manifestations [1, 6]. The sources do not contain comprehensive clinical diagnostic criteria, HPO term mappings, or exclusion lists [1–6]. Consequently:

* **P01**: **Cannot be ruled in or ruled out.** The sources do not provide sufficient clinical diagnostic criteria to exclude or confirm P01 [1–6]. While P01 has spasticity, P01 lacks explicit ataxia or hypomyelination/delayed CNS myelination, but the sources do not state that the absence of these specific terms excludes a patient [1–6].
* **P02**: **Cannot be ruled in or ruled out.** The sources do not provide detailed phenotypic criteria to evaluate P02 definitively [1–6].
* **P03**: **Cannot be ruled in or ruled out.** The sources do not provide diagnostic criteria to rule P03 in or out [1–6].
* **P04**: **Cannot be ruled in or ruled out.** The sources lack exclusion criteria to definitively rule P04 in or out [1–6].
* **P05**: **Cannot be ruled in or ruled out.** P05 has ataxia and spasticity (features in the disorder's name [1–6]), but the sources do not provide complete phenotypic data to definitively rule P05 in or out [1–6].
* **P06**: **Cannot be ruled in or ruled out.** P06 has ataxia and lower limb spasticity [1–6], but the sources lack phenotypic thresholds to rule P06 in or out [1–6].
* **P07**: **Cannot be ruled in or ruled out definitively**, but matches the core manifestations in the disease title. P07 uniquely exhibits "Appendicular spasticity", "Ataxia", and "Delayed CNS myelination", matching the cardinal features of "progressive spastic ataxia and hypomyelination" [1, 2, 3, 4]. However, the sources do not provide formal clinical criteria or genetic data to definitively rule P07 in [1–6].
* **P08**: **Cannot be ruled in or ruled out.** The sources lack the phenotypic details necessary to evaluate or exclude P08 [1–6].
* **P09**: **Cannot be ruled in or ruled out.** The sources provide no diagnostic criteria to rule P09 in or out [1–6].
* **P10**: **Cannot be ruled in or ruled out.** The sources provide no criteria to definitively rule P10 in or out [1–6].

---

### 2. Single Most Likely Patient and Probability

* **Most likely patient:** **P07**
* **Estimated probability:** **90%**

**Reasoning:**
The condition is designated "Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy" [1, 2, 3, 4, 5, 6] and is characterized by "progressive spastic ataxia and hypomyelination" [4]. Among all 10 profiles, **P07** is the only patient presenting with all three core components: spasticity ("Appendicular spasticity"), "Ataxia", and a hypomyelination-related term ("Delayed CNS myelination"). Because exactly one patient in the cohort has the condition, P07 is by far the most likely candidate. The remaining 10% uncertainty accounts for the fact that the provided sources do not include complete diagnostic criteria or individual genetic data [1–6].

---

### 3. Facts Needed to Be Confident (Not Available in the Sources)

To establish a definitive diagnosis, the following information is needed but missing from the sources:
1. **Genotyping / Molecular Analysis:** Evidence of bi-allelic (homozygous or compound heterozygous) pathogenic variants in the *NKX6-2* gene [2, 3, 4, 5].
2. **Comprehensive Clinical Diagnostic Criteria:** Full HPO term listings, phenotypic frequencies, and obligatory clinical features for SPAX8 [1–6].
3. **Exclusion Criteria:** Verified clinical or neuroimaging criteria to formally rule out the other patients who exhibit overlapping features (such as spasticity, ataxia, or cerebellar changes) [1–6].
4. **Neuroimaging Confirmation:** Detailed brain MRI reports confirming hypomyelinating leukodystrophy versus other white matter abnormalities [1, 2, 3, 4, 5, 6].

--------------------------------------------------------------------------------

### Round 2  (picked: P07)

Based on the provided sources, the condition is defined as **Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy (SPAX8)** [2, 3, 4], characterized by progressive neurologic manifestations from diffuse central nervous system involvement [1, 6], specifically **spastic ataxia** and **hypomyelination / hypomyelinating leukodystrophy** [2, 3, 4, 5].

---

### 1. Patient Evaluation (Rule In / Rule Out)

The provided sources contain only brief title and snippet summaries; they do not provide complete diagnostic criteria, comprehensive HPO term lists, or explicit exclusion criteria [1–6]. Consequently, **none of the patients can be definitively ruled in or ruled out with absolute certainty using only these sources**. However, evaluating each against the cardinal features documented in the sources (spasticity, ataxia, and hypomyelination) [2, 3, 4]:

* **P01**: **Cannot rule in or rule out.** The sources do not provide complete feature lists [1–6]. Although P01 has "Lower limb spasticity", they lack the documented "ataxia" and explicit "hypomyelination" named in the disorder [2, 4].
* **P02**: **Cannot rule in or rule out.** The sources do not provide exclusion criteria [1–6]. P02 has "Spasticity", but lacks ataxia and hypomyelination [2, 4].
* **P03**: **Cannot rule in or rule out.** The sources do not provide exclusion criteria [1–6]. P03 has "Gait ataxia", but lacks spasticity and hypomyelination [2, 4].
* **P04**: **Cannot rule in or rule out.** P04 has "Spasticity", but lacks ataxia and hypomyelination [2, 4]. Additionally, P04 has extensive systemic/hepatic involvement (cirrhosis, splenomegaly, hepatic failure) that the sources do not describe, as they emphasize diffuse central nervous system involvement [1, 6].
* **P05**: **Cannot rule in or rule out.** P05 exhibits both "Ataxia" and "Spasticity" consistent with "spastic ataxia" [2, 4], but lacks any neuroimaging finding of hypomyelination/hypomyelinating leukodystrophy [2, 4].
* **P06**: **Cannot rule in or rule out.** P06 exhibits "Lower limb spasticity" and "Ataxia" [2, 4], but lacks neuroimaging evidence of hypomyelination [2, 4].
* **P07**: **Cannot be definitively ruled in** (the sources do not provide a definitive phenotypic profile [1–6]), but is the **best match**. P07 uniquely exhibits all three core manifestations highlighted in the disorder's definition: "Appendicular spasticity" (spastic), "Ataxia" (ataxia), and "Delayed CNS myelination" (hypomyelination) [2, 3, 4].
* **P08**: **Cannot rule in or rule out.** P08 lacks designated spastic ataxia and hypomyelination [2, 4].
* **P09**: **Cannot rule in or rule out.** P09 has dysmetria and intention tremor, but lacks explicit spasticity, ataxia, or hypomyelination [2, 4].
* **P10**: **Cannot rule in or rule out.** P10 has "Lower limb spasticity", but lacks ataxia and hypomyelination [2, 4].

---

### 2. Single Most Likely Patient and Probability

* **Most Likely Patient:** **P07**
* **Estimated Probability:** **85–90%**
  * *Rationale:* The sources explicitly define this entity by the triad of spasticity, ataxia, and hypomyelination [2, 3, 4]. Given the premise that exactly one patient in the cohort has this specific diagnosis, P07 is the only candidate whose profile includes appendicular spasticity, ataxia, and delayed CNS myelination (hypomyelination) [2, 3, 4]. The residual uncertainty exists solely because the sources lack detailed clinical phenotypes and genetic confirmation [1–6].

---

### 3. Facts Needed to Be Confident (Not in the Sources)

To establish diagnostic certainty, the following information is required that the provided sources do not contain:
1. **Direct Genetic Data:** Confirmation of homozygous or compound heterozygous (bi-allelic) pathogenic variants in the *NKX6-2* gene for the patient [2, 3, 5].
2. **Detailed Phenotypic Spectrum:** A complete HPO or clinical profile detailing the frequency of secondary features in *NKX6-2* disease (e.g., whether microcephaly, seizures, optic atrophy, thin corpus callosum, or intellectual disability are typical or atypical) [1, 5, 6].
3. **Explicit Exclusion Criteria:** Information on whether systemic symptoms (such as hepatic or severe multi-organ dysfunction) can occur or if the disease is strictly neurodegenerative/neurological [1, 6].
4. **Formal Brain MRI Criteria:** Specific neuroimaging criteria differentiating "delayed CNS myelination" vs. established "hypomyelinating leukodystrophy" in this specific disorder [2, 3, 4].

--------------------------------------------------------------------------------

### Round 3  (picked: P07)

Based on the provided sources, here is the clinical evaluation:

### 1. Patient-by-Patient Rule In / Rule Out Evaluation

The sources state that the condition is an autosomal recessive disorder characterized by "progressive spastic ataxia and hypomyelination" [4] or "spastic ataxia 8 with hypomyelinating leukodystrophy" [2, 3, 5], causing a "spectrum of progressive neurologic manifestations resulting from diffuse central nervous system" involvement [1, 6]. However, the sources **do not** provide comprehensive HPO lists, detailed phenotyping, or exclusion criteria. Consequently, no patient can be definitively ruled in or ruled out with absolute certainty using only the text provided. Evaluating each against the core manifestations mentioned in the sources:

* **P01:** **Cannot be ruled in or ruled out.** The patient has spasticity ("Lower limb spasticity") and central nervous system manifestations [1, 4], but lacks explicit ataxia or hypomyelination/delayed myelination [2, 4]. The sources do not state whether these specific features rule the condition in or out.
* **P02:** **Cannot be ruled in or ruled out.** The patient has spasticity, but lacks ataxia and hypomyelination [2, 4]. The sources do not provide sufficient detail to rule them out conclusively.
* **P03:** **Cannot be ruled in or ruled out.** The patient has gait ataxia, but lacks spasticity and hypomyelination [2, 4]. The sources do not explicitly state if spasticity is mandatory for diagnosis.
* **P04:** **Cannot be ruled in or ruled out.** The patient has spasticity, but lacks ataxia and hypomyelination [2, 4]. The sources do not detail non-neurological features (such as hepatic or dental abnormalities) to rule them out.
* **P05:** **Cannot be ruled in or ruled out.** The patient displays both "Spasticity" and "Ataxia", aligning with "progressive spastic ataxia" [4], but lacks documented hypomyelination [2, 4]. The sources do not confirm whether leukodystrophy must be clinically noted in every patient.
* **P06:** **Cannot be ruled in or ruled out.** The patient displays "Lower limb spasticity" and "Ataxia" [4], but does not mention hypomyelination or delayed myelination [2, 4].
* **P07:** **Cannot be ruled in or ruled out definitively**, but is the most consistent candidate. P07 possesses "Appendicular spasticity", "Ataxia", and "Delayed CNS myelination", matching the cardinal definition of "spastic ataxia ... with hypomyelinating leukodystrophy" [2, 3] and "progressive spastic ataxia and hypomyelination" [4]. However, the sources do not provide the detailed HPO list required to confirm this diagnosis conclusively.
* **P08:** **Cannot be ruled in or ruled out.** The patient has hypertonia and a broad-based gait, but lacks clear spasticity, ataxia, and hypomyelination [2, 4].
* **P09:** **Cannot be ruled in or ruled out.** The patient has intention tremor and dysmetria, but lacks spasticity and hypomyelination [2, 4].
* **P10:** **Cannot be ruled in or ruled out.** The patient has spasticity, but lacks ataxia and hypomyelination [2, 4].

---

### 2. Most Likely Patient and Estimated Probability

* **Most Likely Patient:** **P07**
* **Estimated Probability:** **~95%**
* **Rationale:** The prompt states that exactly one patient has the disorder. The sources explicitly define the condition as "spastic ataxia 8 ... with hypomyelinating leukodystrophy" [2, 3] and "progressive spastic ataxia and hypomyelination" [4]. P07 is the only individual among the ten who demonstrates the complete triad of spasticity ("Appendicular spasticity"), ataxia ("Ataxia"), and myelination impairment ("Delayed CNS myelination") [2, 3, 4]. 

---

### 3. Facts Needed (and Missing) to Be Confident

To establish a definitive diagnosis, the following information—which is **not** provided in the sources—would be required:
1. **Molecular genetic testing results:** Demonstration of homozygous or compound heterozygous (bi-allelic) pathogenic variants in the *NKX6-2* gene [2, 3, 5].
2. **Complete clinical phenotypic spectrum:** A full listing of characteristic signs, symptoms, and HPO terms associated with *NKX6-2* variants to evaluate the remainder of P07's features (such as arachnoid cyst, microcephaly, and optic atrophy) [1, 5, 6].
3. **Formal diagnostic and exclusion criteria:** Specific guidance on whether hypomyelination on neuroimaging is strictly mandatory and what clinical findings would exclude the diagnosis [1, 4].
4. **Detailed neuroimaging reports:** Specific brain MRI findings detailing diffuse central nervous system hypomyelination characteristic of SPAX8 leukodystrophy [1, 2, 4].

--------------------------------------------------------------------------------

picks across rounds: ['P07', 'P07', 'P07']
